{"filing":{"accession_number":"0001104659-26-071027","cik":"0001815903","ticker":"PTPI","company_name":"Petros Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-06-05","report_date":null,"primary_document":"tm2616064d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1815903/000110465926071027/tm2616064d1_8k.htm"},"events":[{"id":3895,"run_id":3417,"accession_number":"0001104659-26-071027","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The Board approved grants of 7,000,000 restricted shares to four executives and directors (Silverman, Bernstein, Boctor, and Walker) with a two-tranche vesting schedule (50% immediate, 50% at six months). This is a compensatory arrangement for named executives and directors, clearly falling under Item 5.02(e) disclosure of equity grants. The aggregate size and broad distribution to senior leadership makes this material to investors.","company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","filing_date":"2026-06-05","items":[{"id":4933,"accession_number":"0001104659-26-071027","item_number":"5.02","item_title":"Departure of Directors or Certain Officers;","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Board approved grants of 7,000,000 restricted shares to four executives and directors (Silverman, Bernstein, Boctor, and Walker) with a two-tranche vesting schedule (50% immediate, 50% at six months). This is a compensatory arrangement for named executives and directors, clearly falling under Item 5.02(e) disclosure of equity grants. The aggregate size and broad distribution to senior leadership makes this material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T21:03:32.390067+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4933,"accession_number":"0001104659-26-071027","item_number":"5.02","item_title":"Departure of Directors or Certain Officers;","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Board approved grants of 7,000,000 restricted shares to four executives and directors (Silverman, Bernstein, Boctor, and Walker) with a two-tranche vesting schedule (50% immediate, 50% at six months). This is a compensatory arrangement for named executives and directors, clearly falling under Item 5.02(e) disclosure of equity grants. The aggregate size and broad distribution to senior leadership makes this material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T21:03:32.390067+00:00","company_name":"Petros Pharmaceuticals, Inc.","ticker":"PTPI","filing_date":"2026-06-05"}]}